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ABSTRACT 
The effect on reversal of dilation of two different doses of REV-EYES 
(dapiprazole HCI), the recently introduced anti-mydriatic, was 
investigated in this study. The manufacturer's recommended dose, 
and exactly half that dose were compared in a double masked 
crossover study design. Subjects were dilated with 2.5% 
phenylephrine and 1% tropicamide. The pre and post dilation 
variables examined were near and far visual acuity, accommodative 
amplitude, pupil diameter, subjective symptoms, conjunctival 
injection, and corneal epithelial integrity by fluorescein staining. The 
60 subjects that participated ranged in age from 21 to 67 years (mean 
= 28.6 years), in eye color (32light and 28 dark), and in refractive 
status (11 emmetropes, 42 myopes, and 7 hyperopes). The results 
demonstrated that the half dose was functionally equivalent to the 
full dose in reversing the effects of dilation with fewer subjective 
symptoms of discomfort. No dependent relationship was found 
between iris color and the two different doses of REV -EYES. 
KEY WORDS: REV-EYES, dapiprazole, dose, mydriasis, 
phenylephrine, tropicamide, alpha-adrenergic blocker 
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INTRODUCTION 
Dilation of the pupil for adequate examination of the fundus is now 
the standard of care in optometry .I Failure to dilate is the most 
prevalent reason for optometrists being charged with negligence for 
not diagnosing ocular diseases.2 However, the post dilation stage 
often leaves the patient with blurred vision, decreased 
accommodative amplitude, photophobia, and concern about 
performing certain visual tasks such as driving. This can make the 
patient apprehensive about dilation. Due to these post dilation side 
effects, safe reversal of mydriasis would be desirable to return the 
patient to his/her pre-dilated state.3 Safe reversal of dilation may 
even become part of the standard of care in the eye care profession.2 
Pilocarpine, a cholinergic miotic, has been investigated for this use, 
however, its actions may be more harmful than helpful.4 Pilocarpine 
causes undesirable accommodative spasm, thickening of the 
crystalline lens, and shallowing of the anterior chamber which can 
potentiate pupillary block .s Studies involving thymoxamine , an 
alpha-adrenergic blocker, have shown that it is effective in reversing 
mydriasis with mild irritation, but is most effective only with blue 
colored irides.6 
Dapiprazole HCl, manufactured by Abbott Laboratories and 
marketed by Storz Ophthalmics as REV-EYES, is an alpha-
adrenergic blocker currently approved and available to practitioners 
for the reversal of mydriasis. Dapiprazole HCl, which is 5,6,7,8-
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tetrahydro-3-[2-(4-o.tolyl-1-piperazinyl)ethyl]-s-triazolo[4,3-a] 
pyridine hydrochloride, exerts its effects by competing for receptor 
sites on the iris dilator, thus blocking its action and causing 
relaxation of the radial iris muscle. Reversing mydriasis in this way 
cannot favor pupil block, and it has been found that dapiprazole 
decreases lOP, whereas, thymoximine does not.7 Dapiprazole does 
not have any affect on heart rate or blood pressure.s When applied 
topically, dapiprazole that reaches the endothelium has no toxic 
affect on the rabbit cornea.9 Studies using ultrasonographic 
techniques show that dapiprazole used topically has no effect on 
accommodation, as determined by changes in the anterior chamber 
depth and lens thickness.s 
The adverse side-effects of dapiprazole include: stinging upon 
instillation, conjunctival injection, lid edema and redness, corneal 
staining, tearing, dryness, photophobia, blurred vision, browache, 
headache, and prolonged miosis.s 
Studies concerning the effectivity of dapiprazole when used to 
reverse dilation show that it is most effective when phenylephrine is 
used alone; complete reversal of mydriasis occurs within an hour.lO 
Literature from the company states that 67% of eyes were reversed 
at one-half hour, and 88% of eyes were reversed at one hour. 
Dapiprazole is less effective when tropicamide is used for dilation 
(either alone or in combination with phenylephrine), and it usually 
takes about two hours for reversal of the pupil diameter .to 
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In order to attain quick and wide mydriasis, both an adrenergic 
agent (which enhances the iris dilator) and an anticholinergic agent 
(which relaxes the iris sphincter and ciliary muscle) should be used in 
combination. Phenylephrine and tropicamide have onset and 
duration times that are similar.ll Using the two in combination 
offers the most complete dilation. Using each alone will still allow 
some pupillary constriction when a bright light source, such as a 
binocular indirect ophthalmoscope, is presented. The two drugs in 
conjunction also enable the ciliary muscle to be relaxed so that 
- uncomfortable ciliary spasm can be avoided when such a bright light 
is shone into the eye.ll For dilation purposes it is standard at Pacific 
University College of Optometry clinics, as is common with many 
practitioners, to use a combination of 2.5% phenylephrine and 1% 
tropicamide. 
Although REV-EYES is approved only for the reversal of mydriasis 
by topical ocular instillation, intraocular administration of 
dapiprazole to induce miosis after extra capsular cataract extraction 
has been investigated; it was found to be rather comparable to 
acetylcholine with respect to reducing postoperative pressure rise, 
but dapiprazole has a slower onset and longer duration.12,13 The use 
of dapiprazole with epinephrine for treating primary angle closure 
glaucoma has also been studied, and in the opinion of the authors the 
combination appears to be a good choice.14 
Most published literature to date, including that mentioned above, 
has been concerned with the reversal rate of pupil diameter. 
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However, to the dilated patient, an enlarged pupil diameter is not 
the only significant functional problem. Additional studies have 
addressed the effect of dapiprazole on other isolated physiological 
components such as accommodation or anterior chamber depth, but 
none have examined the clinically relevant functional benefits to the 
patient. In addition, clinical impressions at Pacific University from 
the preliminary use of REV-EYES have suggested that a dosage 
reduced from that recommended by the manufacturer may be 
functionally adequate and in some cases, more desirable from the 
patient's perspective. 
The purpose of this study is to avail practical information regarding 
the use of REV-EYES to eye care practitioners to afford maximum 
benefit with minimal adverse effects to their patients. We examined 
several variables that may affect a practitioner's decision to use this 
drug, not use this drug, or use a dose different than that 
recommended. We compared our subjects' ocular physiological 
response and visual performance via measurement of pupil 
diameter, accommodative amplitude, far and near visual acuities, 
subjective comfort, and observed side effects for the natural, non-
pharmacologically induced reversal process, and for two different 
doses of REV-EYES, the full recommended dose and one half the 
recommended dose. 
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METHODS 
The subjects in the study were volunteer students and their families 
at the Pacific University College of Optometry. Of the 60 subjects, 30 
were male and 30 were female. The mean age was 28.6, and the age 
range extended from 21 to 67 years old. Other subject variables 
considered were: iris color (32 light; 28 dark) and refractive error (11 
ernmetropes; 42 myopes; 7 hyperopes). Subjects with dark irides 
were Caucasian, Asian, Hispanic, and Indian. 
Potential subjects that were excluded from participation in the study 
included: those under the age of 18; pregnant women and nursing 
mothers (as suggested by the manufacturers of REV-EYES); those 
with a history of anterior uveitis, diabetes, hypertension, or any 
medical contraindications for dilation; and those with any form of 
pupil/iris abnormality, pathological or physiological anisocoria, 
amblyopia or functional inequalities between the two eyes, current 
use of ocular medication, or ocular or systemic contraindications or 
allergies to any of the ophthalmic drugs used in this study 
(proparacaine 1%, phenylephrine 2.5%, tropicamide 1%, or 
dapiprazole HCl 0.5%). 
Full ethical research consent was obtained from the Institutional 
Review Board Human Research Approval Committee prior to any 
clinical research. A written informed consent form including a 
description of the study, exclusion criteria, risks, benefits, and a 
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freedom to withdraw statement, was read and signed by all subjects 
prior to their participation. 
The design of the study consisted of two phases. The first phase 
involved a standard dilation of both eyes of each subject without the 
instillation of REV-EYES. The second phase consisted of a standard 
dilation of both eyes which was interrupted after 45 minutes with the 
randomized instillation of either the experimental half dose or the 
control full dose of REV-EYES into each eye. The first and second 
phases were separated by at least seven days . . 
PHASE ONE 
The first phase served as a baseline data resource. From these data 
we were able to determine if each of the subject's eyes responded 
equally to the mydriatic agents on all variables, as we planned to use 
a crossover experimental design where one eye serves as a control 
for the other in phase two. Also from this data we were able to make 
statements about certain dilating characteristics of the different sub-
samples of the subjects. This baseline also allowed us to compare the 
effectivity and benefits of using REV -EYES as an anti-mydriatic 
versus a natural reversal process. 
In the first phase, for both the left and right eyes of each subject the 
following variables were measured: pupil size, Donder's 
accommodative amplitude, and best corrected distance and near 
visual acuity. Methods of measurement of each of these variables 
are described later in this section. 
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After these measurements were recorded, and the subject was 
deemed safe for standard dilation (a complete optometric 
examination within the six previous months was required), one drop 
each of proparacaine 1%, phenylephrine 2.5%, and tropicamide 1% 
was administered, separately, into the conjunctival sac of each eye. 
Punctal occlusion to limit systemic absorption was performed by the 
subject. 
Anesthetic was used before the dilation to both decrease the 
irritation of the medication and also enhance the corneal 
permeability to the dilating drugs. By eliminating the stinging, both 
lacrimation and the blink response are decreased, thereby decreasing 
drug dilution and nasolacrimal drainage.16 The goal here was to 
simulate a standard clinical situation, and to achieve maximum 
dilation. 
After the drops had been administered, the subject returned to have 
each of the variables measured at 45 minutes, 75 minutes, 105 
minutes, and 24 hours following drop instillation. This time schedule 
was adopted so that cross-comparisons could be made to the time 
schedule used in phase two. 
The 45 minute interval was selected as the first time interval for two 
reasons: 1) this is the approximate time that the subjects would be 
reaching their maximum pupil dilation with phenylephrine and 
tropicamide11, and 2) in clinical optometric setting, this is about the 
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length of time required after instilling the drugs to wait for sufficient 
dilation, to perform a thorough fundus examination, and to discuss 
findings with a patient, after which the REV-EYES might be instilled. 
Thus, in the second phase of the study the introduction of REV-EYES 
occurred at 45 minutes to simulate clinical practice. 
PHASE TWO 
The second phase of the study consisted of dilating both of the 
subjects' eyes, and then randomly introducing either a control dose 
(manufacturer's recommended) or experimental dose (half of the 
recommended) of REV -EYES into each of their eyes to iatrogenically 
reverse the mydriasis. 
At the start of the second phase each of the subject's eyes had the 
following variables measured: pupil diameter, Dander's 
accommodative amplitude, best far and near visual acuity, 
conjunctival injection, and corneal staining. Again, the measurement 
techniques used are described later in this section. 
Dilation was once more achieved with proparacaine 1%, 
phenylephrine 2.5%, and tropicamide 1%. At the 45 minute time 
interval (45 minutes post dilation/pre REV-EYES) measurements 
were again taken. At this point, each of the subject's eyes randomly 
received either the experimental half dose or the control full dose of 
REV-EYES. In this manner, one of the eyes served as a control for 
the other. This was valid since in the first phase we had shown that 
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there were no significant differences between the responses of either 
the right or left eyes of each subject (see Results). 
The control dose used in this study was the manufacturer's suggested 
dose, as written both on the bottle and in the instruction set enclosed 
with the drug packaging: two drops in quick succession, a five minute 
time interval, followed by another two drops in succession into each 
eye. 
The manufacturer of REV-EYES chose to use a gravity-feed dropper 
as the dispenser of REV-EYES. This type of bottle delivers only 
approximately half (25 microliters) of a standard dropper's single 
drop. Clinically, the gravity-feed dropper permits instillation of 
precise and consistant volumes of drug onto the cornea. Since the 
conjunctival sac only holds 30 microliters without overflow16, the 
purpose of the two drops in quick succession (50 microliters) is to 
insure that enough drug actually reaches the eye. 
The experimental dose selected for this study is simply one half of the 
recommended dose, that is, two drops from the gravity-feed dropper 
in quick succession. The benefits of using half of the recommended 
dose to the eye care practitioner are primarily that of time and cost 
effectiveness, however, these and other potential benefits to the 
patient will be discussed at further length in the discussion section of 
this paper. 
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To achieve the experimental dose without subjects being aware that 
they were receiving only half as much drug in one eye, the second set 
of two drops was replaced with two drops of preservative free 
artificial tears dispensed from a drug-free and sterilized REV-EYES 
bottle. These bottles were marked with a small dot so that the 
researchers were aware of the contents of the bottle. To the subjects, 
it appeared as though they were receiving all of their drops from a 
standard REV -EYES bottle. Therefore, the experimental dose 
consisted of two drops of REV-EYES, followed by a five minute 
interval, then two drops of artificial tears from the second sterilized 
REV-EYES bottle. 
The study was designed to be double masked. Neither the subject nor 
the researcher taking the measurements were aware of which eye 
had received the control or experimental dose. All clinical 
measurements were taken by the same two researchers throughout 
the extent of the study. The subjects were arranged so that one 
researcher would perform all drop administration, including the 
randomized REV-EYES dosages on one subject, but would do none 
of the variable measurements on this same subject. 
Following the administration of the two different doses, the subject 
was required to return for measurements at the following intervals: 
30 minutes, 60 minutes, and 24 hours post REV-EYES. 
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In the period between 60 minutes and the 24 hour follow up, all 
subjects were instructed not to use any lubricant drops or 
vasoconstrictors on either eye. 
The major variables during both the first and second phase which we 
examined were: 
PUPIL SIZE: 
Pupil size was measured using a Cogan pupillometer. This 
consisted of a pair of black opaque goggles, and a strip of black 
paper with sets of 2 adjacent pinholes, successively separated 
every half millimeter.ls Before the study began, each subject 
was instructed on the use of the pupillometer (measurements 
are, hence, subjective in nature). The subject was instructed to 
put on the goggles, cover the left goggle with the palm of the 
hand, place the black paper strip over the right side of the 
goggles and look up at the light source (standard fluorescent 
lighting). The subject was then able to see several sets of two 
adjacent circles of light as they scrolled the black paper up and 
down along the goggle. Depending on the subject's pupil size 
and the various separations in the pinholes, some sets of circles 
would appear overlapping, while some would appear 
completely separated. The subject was instructed to find the 
set of circles such that the two circles of light just touched ( 
where they did not overlap or remain separated). This was to 
be indicated to the researcher. The subject was informed that 
the circles may appear to move (this is due to fluctuations in 
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accommodation), and that if no set of circles just touched, the 
set of circles that was barely overlapping should be chosen. 
For ease of subject understanding, examples of what they 
should expect to see were drawn for them, and each subject 
was instructed to practice the technique a few times. All 
subjects quickly became very skilled in measuring their pupils in 
this manner. 
DONDER'S ACCOMMODATIVE AMPLITUDE: 
Measurements of an effective nearpoint were made using a 
standard Donder's card. Subjects were instructed to bring the 
card as close to their eyes as possible until the 0.62M print was 
too blurry to read. All measurements were made monocularly 
in centimeters with a pull out tape measure (one end at the 
plane of the eye and the other at the plane of the card). 
BESTVISUALACUITY ATFAR(BVAFAR): 
Distance visual acuity was measured through the subject's 
refractive correction at six meters using a projected Snellen 
acuity chart under standard room illumination. All 
measurements were taken monocularly. 
BEST VISUAL ACUITY AT NEAR (BVA NEAR): 
Near visual acuity was measured through the subject's near 
correction (which was a bifocal for some subjects) at 40 
centimeters using a reduced Snellen acuity card under standard 
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room illumination with a near point light. All measurements 
were taken monocularly. 
Additionally, in the second phase, each subject was evaluated for 
signs of injection or corneal staining at the various time intervals. 
CONJUNCTIVAL INJECTION: 
Injection was rated on a scale of zero to four, where zero indicates 
no injection and four indicates very severe injection. See Table 1. 
TABLE 1: Conjunctival Injection 
Grade 0: None 
1: Minimal conjunctival injection, no chemosis 
2: Moderate conjunctival injection, no chemosis 
3: Moderate conjunctival injection, moderate chemosis 
4: Severe con'unctival in'ection and chemosis 
CORNEAL STAINING: 
Staining also was graded on a scale of zero to four, four denoting 
the most severe superficial punctate erosion. The amount of 
staining was assessed using fluorescein strips hydrated with sterile 
saline. See Table 2. 
TABLE 2: Corneal Staining 
Grade 0: Absent 
1: Countable dots 
2: Increase in number of countable dots, with some clumping 
3: Coalescent macropunctate fluorescence 
4: Com lete coalescence, with e ithelialloss 
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SUBJECTIVE SURVEY: 
Symptoms were evaluated by the subjects at two points during the 
second phase. Immediately following the administration of REV-
EYES, each subject was asked by the researcher who did not 
administer the drops to rate the stinging/ discomfort of the drops on 
a scale of one to seven, where 'one' indicates 'none' and 'seven' 
ranks 'severe'. At 30 minutes post REV-EYES administration the 
subjects were given a written questionnaire to fill out. The subjects 
ranked the following symptoms on a scale of one to seven (none to 
severe): 
Eye itching 
Eye dryness 
Tearing 
Sensitivity to bright lights 
Headache or browache 
Lids: red, puffy or itchy 
Eye redness; "How red do your eyes look?" 
To increase awareness of any differences in appearance between 
eyes, all subjects were instructed to cover the fellow eye with a palm, 
and to look at each eye separately (each subject was given a mirror 
to use). 
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RESULTS 
In this crossover study design, since right and left eyes of each subject 
received a different dose of REV-EYES, it was essential that we 
establish there was no difference between the subject's eyes for the 
variables we chose to measure: pupil diameter, Donder's amplitude, 
near acuity, and far acuity. The phase one dilation data served as a 
baseline for this purpose. Our analyses showed that there were no 
significant differences between the left and right eyes of the subjects 
on any of the variables measured using both a two tailed paired t-
test analysis and a two-way ANOV A (analysis of variance) with 
repeated measures (p<O.OS). Therefore, since both eyes of each 
subject responded the same for the variables measured, one eye 
could serve as a control for the other. 
The results from the phase two dilation, where the two different 
doses of REV-EYES were used to reverse the mydriasis, were 
analyzed using a two tailed paired t-test and a two-way ANOV A 
with repeated measures at a level of significance of p<O.OS. The 
effectivity of the full and half dose on each of the variables was 
compared. Near visual acuity, pupil diameter, and Donder's 
accommodative amplitude were the dilation variables found to be 
significantly different with respect to dosage when two tailed paired 
t-test analysis was used. See Table 3;Figures1,2,&3. However, 
when comparing the variables using a two-way ANOV A, there were 
no significant differences found across time between the full dose 
and the half dose on any of the variables measured. That is, the 
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mydriatic reversal accomplished using the half dose of REV-EYES 
was statistically the same as for the full dose of REV-EYES. 
The effects of a drug induced mydriatic reversal were also compared 
to a natural, without administration of REV-EYES, reversal. These 
were analyzed using a two tailed paired t -test. Differences (p<O.OS) 
in pupil size, accommodative amplitude, and NV A were found when 
using no drug compared to using either dose of REV-EYES. See 
Table 3. 
We also examined the data to see if there were any differences in the 
extent to which subjects with light or dark irides were affected by the 
two different doses of REV-EYES. With the t-test analysis, there 
was no difference (p>O.OS) between the effectivity of the full or half 
dose when used on subjects with light or dark irides with respect to 
any of the variables across time. Both the full and half dose affected 
each group equally. However, the unpaired t-test showed that 
subjects with light irides returned to their baseline near acuity and 
pupil diameter faster than subjects with dark irides. See Table 4; 
Figures Sa, &5b. This difference is independent of whether the full or 
half dose was used. 
Two-way ANOV A statistics also showed no significant difference 
between iris color and either dosage. However~ there was a 
significant relationship over time with respect to iris color and pupil 
size with both doses of REV-EYES. The light iris group showed 
larger pupil sizes initially, 5.14 mm versus 4.76mrn, (before 
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administration of any mydriatic agents), but at and after 
administration of either dose of REV-EYES, they had smaller pupils 
than the dark iris group (at time zero minutes, 30 minutes, and 60 
minutes). This suggests that subjects with light iris color reacted 
more quickly to REV-EYES than those with darker iris color. 
Each of the subjects completed the subjective survey, and their 
responses were analyzed using descriptive statisics, a percentage 
distribution, and the Wilcoxon signed-rank test (Z>1.65, p<O.OS). See 
Table 5; Figures 6,7,8,9,&10. 
Each subject was objectively examined under double masked 
conditions to determine the level of conjunctival injection and 
corneal staining due to the instillation of REV-EYES. These 
measurements were taken before REV-EYES instillation, and at 30 
minutes, 60 minutes, and 24 hours after instillation of REV-EYES. 
The results were also analyzed using the Wilcoxon signed-rank test 
(Z> 1.65, p<O.OS). See Table 6. 
The two-way ANOV A test also showed that there was a significant 
difference in objectively measured conjunctival injection between the 
full and half dose of REV-EYES: the full dose causing significantly 
more conjunctival injection than the half dose (p=0.0008). There was 
no significant difference in corneal staining with the ANOV A. 
Our statistical analysis included one-way ANOV A comparisons of 
emmetropic, myopic, and hyperopic subjects in the first baseline 
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phase of the study. There were no significant differences between 
these three groups with respect to far or near acuity, or pupil size. 
However, comparisons of these samples revealed that the hyperopic 
subjects have a significantly worse Donder's accommodative 
amplitude than the myopes or the emmetropes at all times of 
measurement including the initial measurement (p< 0.05). See 
Figure 11. The manner in which the different refractive status 
groups were affected by the two doses of REV-EYES, with respect to 
the variables measured, was analyzed using two-way ANOV A 
statistics. The only significant difference found was that the myopes' 
accommodative amplitude returned faster than the other two 
groups, but only with the full dose (p=0.0136). See Figures 12&13. 
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Table 3: Full Dose, Half Dose, and No Dose of REV-EYES 
DILATION 
VARIABLE 
10.367 
20/20 
0 8.058 
56.4 
30 MIN S 
1 9 
Table 4: Reversal Rates of Light and Dark Irides 
VARIABLE 
PUPIL SIZE 4.77 
4.75 
20120 
20120 
8.071 
8.071 
201110.35 
201110.35 
30 MINUTES 
,.·:·:=. 
20 
Table 5: Subjective Symptoms 
SYMPTOMS 
TEARING 
HEAD/BROW ACHE 
LID REACTION 
PERCEIVED REDNESS 
INITIAL DISCOMFORT FULL 4.075 
OF DROPS HALF 3.925 
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Table 6: Conjunctival Injection and Corneal Staining 
MEAN 
TIME OBJECTIVE MEASURE CUE RANKING 
BASELINE INJECTION FULL& HALF 0.267 
STAINING FULL& HALF 0.008 
OMINUTES INJECTION FULL& HALF 0.592 
STAINING FULL& HALF 0.2 
30 MINUTES 
60 MINUTES 
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Figure 1 
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PUPIL S1ZE vs TIME (LIGHT/DARK IRIDES) 
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Figure 7 
SUBJECTIVE RATING OF HEAD/BROW ACHE 
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SUBJECTIVE RATING OF LID REACTION 
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SUBJECTIVE RATING OF PERCEIVED REDNESS 
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Figure 10 
SUBJECTIVE RATING OF DROP DISCOMFORT 
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DONDER'S AMP. vs TIME WITH NO DOSE (REFRACTIVE STATUS) 
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Figure 12 
DONDER'S AMP. vs TIME WITH FULL DOSE (REFRACTIVE STATUS) 
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DONDER'S AMP. vs TIME W1ITH HALF DOSE (REFRACTIVE STATUS) 
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DISCUSSION 
Evaluation of our data showed that for the most part, there was no 
significant difference between the full and half doses of REV-EYES, 
and those differences that did exist were not clinically significant 
when comparing the subjects' visual performance and physiological 
response. However, in our subject sample, the half dose achieved 
equivalent reversal results as the full dose with overall statistically 
and clinically significant fewer side effects. Since the purpose of 
drug treatment is to achieve the desired effect while avoiding as 
many side effeCts as possible, the use of the half dose would be 
beneficial to both the practitioner and the patient. The patient would 
return to his or her pre-dilated state with less discomfort, and the 
practitioner would both reduce the time needed to retain the patient 
for administering the full sequence of REV-EYES, and would 
increase the number of patient doses per bottle. 
When comparing the effects of the full and half dose of REV-EYES on 
pupil diameter, we found that there were significant differences at 30 
minutes (df=59,p=0.0001) and at 60 minutes(df=59,p=0.0001) 
following REV-EYES administration with a two tailed t-test, but 
there was no significant difference found with the two-way ANOV A 
at any time interval. These differences were only 0.2 mm at time 30 
minutes and 0.324 mm at time 60 minutes. Clinically, these 
differences are very small and would be unnoticeable to patients. 
Near visual acuity was also found to be significantly different 
between the full dose and the half dose at 30 minutes and 60 minutes 
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post REV -EYES with the t-test, but not with the ANOV A. Thirty 
minutes following instillation, the average near acuity of the half 
dose eyes was 20/47, whereas, the acuity of the eyes with a full dose 
was 20/42. At 60 minutes, near acuity with a half dose was 20/28, 
and with a full dose was 20/26. These differences do not represent 
even one line of acuity on a reduced Snellen acuity card and are, 
therefore, irrelevant clinically.· 
There was a significantly different Donders accommodative 
amplitude at 60 minutes between the full and half dose eyes when 
analysis was done using a two tailed t-test (p=0.0196). The mean 
Donders amplitude at time 60 minutes with the full dose was 18.12 
em, and with the half dose was 23.32 em. Both amplitudes are within 
a comfortable near working distance range. There was no 
significant difference in Dander's amplitude at time 30 minutes 
between the full and half doses. Two- way ANOV A with repeated 
measures showed that there was no significant differences with 
respect to accommodative amplitude and dosage over time. 
There were no differences found between the full dose and half dose 
with respect to recovery of distance visual acuity with either t-test 
analysis or with the two-way ANOV A. Dilation with a 
phenylephrine and tropicamide combination caused most subjects to 
lose about one of line of acuity on a distance Snellen chart. 
Moreover, return to pre-dilation distance acuity levels was not 
enhanced by any amount of REV-EYES, as there was no significant 
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difference between the natural reversal process of dilation and a 
drug-induced reversal for this variable. 
We also wanted to establish whether dark or light irides reacted 
differently to the two doses of REV-EYES examined in this study. In 
the first phase baseline dilation, our sample showed no significant 
difference in any of the variables between subjects with light or dark 
irides. Our findings do not support the observed clinical tendency 
for light and dark irides to dilate at different rates and magnitudes. 
This may be due to the fact that subjects in our study designated as 
having dark irides were predominantly (67.8%) caucasian subjects 
with darkly pigmented eyes. The tendency for differing dilation rates 
pertains more specifically to black or darkly pigmented people with 
dark irides 16. In our study, the remaining 32.2% of the dark iris 
subjects were Asian, Hispanic, and Indian. 
From the results of our sample, it appears as though iris color alone 
is not a sufficient consideration when clinically determining whether 
to use the full or half dose. 
Our second phase data also revealed that regardless of whether the 
full or half dose of REV-EYES was used, subjects with light irides 
demonstrated a faster rate of reversal from dilation. Subjects with 
light irides showed a faster return to baseline with near acuity as 
well as with pupil diameter. See Table 4, Figures Sa and Sb. Thirty 
minutes following the instillation of the half dose of REV -EYES, 
subjects with light irides were able to read two lines better near 
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acuity than subjects with dark irides, although this was not 
statistically significant due to high intersubject variablility. At this 
point these subjects also had a O.Smm smaller pupil diameter. These 
two differences remained the same at the one hour interval after 
REV-EYES. 
The full dose did not return either of these variables to baseline any 
faster than the half dose. A patient with light irides could be 
expected to return to baseline equally fast with either the full or half 
dose. 
No difference in accommodative amplitude, or distance visual acuity 
was found between light and dark irides with either dose. 
One of the most significant variables involved in the decision 
whether or not to use REV -EYES as an anti-mydriatic may be the 
patient's response to its side effects. The side effects in our study that 
showed a significant difference in subjective ranking between the full 
and half dose were: (1) tearing , (2) headache /brow ache , (3) 
puffy /red/itchy lids, and (4) perceived redness of the eyes. See Table 
5. 
The most significant side effect was how red the subjects perceived 
their own eyes to be when comparing between the eye with the full 
dose and the eye with the half dose. Without knowing which eye had 
received which dose, 66.7% of the subjects rated their full dose eye to 
be moderately to severely red (grade four to seven out of seven), 
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whereas, only 34.9% of the subjects rated their half dose eye to be as 
red. 
The modal value (representing 30% of the subjects) for redness 
rating for the full dose eyes was a grade six out of seven. With the 
half dose eye the modal value (25% of the sample) of redness was a 
grade two out of seven. This represents a significant difference in 
the perceived redness of the subjects' eyes, and represents an 
important variable for the practitioner to consider before 
administering the full dose of REV-EYES. 
The conjunctival injection of the subjects' eyes was also evaluated by 
the researchers before REV-EYES instillation, and at 30 minutes, 60 
minutes, and 24 hours after the instillation of REV-EYES (see Table 
6). A significant difference in conjunctival injection was found 
between the eye receiving the full and the half doses at all time 
intervals with T-test analysis (p=O.OOOl), and with ANOVA across 
time (p=0.0008). The comparative injection of the eyes showed the 
most difference one hour after REV-EYES, however, there was still a 
significant difference in injection between eyes the next day. 
Subjects also responded that there was a significant difference 
between the full and half dose on the comfort of their lids. Of the 
subjects, 8.3% rated a stong lid reaction (grade four to seven) on the 
. 
eye which received the full dose, whereas, only 3.2% rated an equally 
strong reaction with the eye which received the half dose. 
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While the majority of the sample rated their reflex tearing to be 
minimal in both eyes (grade one or two), 5% of the subjects rated the 
full dose eye as having moderate to severe tearing. No subjects 
rated their half dose eye to be tearing as severely. 
The majority of the subjects felt no related onset of browache or 
headache with either the full or half dose, and rated this side effect to 
be grade one or two. However, 5% of the sample felt a moderate to 
severe browache (grade four to seven) occurred over the eye that 
received the full dose. There were no subjects who rated a grade 
four to seven browache over the half dose eye. 
Objectively, each subject was also examined for corneal staining 
before instillation of REV-EYES, and at 30 minutes, and 60 minutes 
after instillation of REV-EYES . See Table 6. There was a significant 
difference in staining both at 30 minutes, and at 60 minutes, with the 
full dose eye staining more than the half dose eye. These results may 
indicate a difference in overall subject comfort experienced as a 
result of the drug instillation, and may also relate to the difference 
found between the tearing and comfort of the full and half dose eyes 
(that is, the more irritated eye tearing more). 
Subjective side effects which did not differ by dosage were: eye 
itching, eye dryness, sensitivity to bright lights, and initial discomfort 
of the drops. 
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Although the subjects found no difference between the two doses on 
these side effects, their overall ratings were still important. On 
overall subjective rating of the discomfort of the drops, 71.7% of the 
subjects gave stinging a moderate to severe rating (grade four to 
seven out of seven), whereas, only 28.3% felt the stinging was mild 
(grade one to three). 
All subjects (100%) rated the eye itching to be mild (grade one to 
three), and almost all subjects (96.4%) felt there was only mild 
dryness related to the drops of either of their eyes (grade one to 
three). Also, 63.3% of the subjects felt a moderate sensitivity to lights 
(grade three to five) which was equal whether the half or full dose 
was used. 
Due to the range of responses on the subjective survey, it is apparent 
that each patient will respond differently to REV-EYES. Therefore, 
it is critical to involve the individual patient in the decison of whether 
or not to use REV-EYES. It is important that the practitioner 
evaluate the patient to determine how sensitive to other procedures 
and ophthalmic drugs he or she may be. A patient who is extremely 
sensitive in most instances will probably be bothered by the side 
effects of this drug. 
Many subjects in our study had strong opinions of the drug, whether 
they felt the benefits outweighed the side-effects or not. One subject 
reported an intense browache that kept him awake for a part of that 
night, and which was not relieved with aspirin. Another subject had 
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a strong hyperemic and edematous reaction beyond that which might 
be considered appropriate to iatrogenically induce. However, there 
were subjects who were very pleased with the effects of REV-EYES, 
and would not want to be dilated again without the option of using 
this drug. All in all, when subjects were asked if they would want to 
use REV-EYES again, 75% of the 48 subjects responding said that 
they would. 
CONCLUSIONS 
In conclusion: 
1. We determined REV-EYES to be effective in accelerating 
the physiological and functional recovery from dilation with 1% 
tropicamide and 2.5% phenylephrine, measured by near visual 
acuity, pupil size, and accommodative amplitude. 
2. There were no clinically important differences between the 
full and half doses of REV-EYES, although statistically significant 
differences existed. 
3. There were clinically and statistically significant differences 
in subjective discomfort and side effects; subjects tolerated the half 
dose better than the full dose. 
4. In our sample, the half dose was found to be equally 
effective to the full dose with fewer side effects regardless of iris 
color. 
From the evaluation of our data, it became apparent that there are 
certain patients that would benefit most from the use of REV-EYES. 
These include: 
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1. Hyperopic patients. REV-EYES may act as an important 
drug for reversing the effects of dilation/ cycloplegia in patients who 
are moderate to significant uncorrected or partially corrected 
hyperopes. Functionally, this means that the use of REV-EYES 
following dilation of hyperopic patients may ease the transition in 
returning to work or a task where a near point demand is required. 
2. Patients who have to perform visually dependent tasks 
requiring near work. 
3. Those patients that are apprehensive about, or have a 
history of having difficulty driving following dilation. 
4. Patients with narrow angles or shallow anterior chambers 
where dilation is necessary, but where quick reversal is desired. 
REV -EYES can be used to pass more quickly through the most 
dangerous mid-dilated state. This may also decrease the time that 
these patients need remain in the office to be monitored. 
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